These Policies are designed to mitigate damage caused by *Phytophthora lateralis.*

Current Forest Service management direction requires all management activities within the range of Port-Orford-Cedar conform to guidelines described in the Siskiyou Forest Plan in Oregon and the Six Rivers, Klamath, and Shasta-Trinity Forest Plans in California.

The responsible official for the Forest Service is the Pacific Northwest Regional Forester.

The responsible official for the Bureau of Land Management is the Oregon/Washington State Director.

Charles Wassinger,

Acting State Director, Bureau of Land Management.

Richard W. Sowa,

Acting Regional Forester, U.S. Forest Service, Region 6.

[FR Doc. 03–3172 Filed 2–7–03; 8:45 am]

BILLING CODE 4310–33–P; 3410–11–P

DEPARTMENT OF AGRICULTURE

Forest Service

Notice of Resource Advisory Committee Meeting

AGENCY: Lassen Resource Advisory Committee, Susanville, California, USDA Forest Service.

ACTION: Notice of the meeting.

SUMMARY: Pursuant to the authorities in the Federal Advisory Committee Act (Public Law 92–463) and under the Secure Rural Schools and Community Self-Determination Act of 2000 (Pub. L. 106–393) the Lassen National Forest's Lassen County Resource Advisory Committee will meet Thursday, February 13, 2003, in Susanville, California for a business meeting. The meetings are open to the public.

SUPPLEMENTARY INFORMATION: The business meeting February 13, 2003 begins at 9 a.m., at the Lassen National Forest Headquarters Office, Caribou Conference Room, 2550 Riverside Drive, Susanville, CA 96130. Agenda topics will include: Review previous meeting minutes and approve, Approve Meeting Agenda, Review previous meeting minutes and approve, Discuss attendance of 6th Annual National Forest Counties & School Coalition Conference March 28–30 in Reno, Review Workshop Results, Use Rating System with Submitted Proposals and Review Proposals. Public Comment Time will also be set aside for public comments at the end of the meeting.

FOR FURTHER INFORMATION CONTACT: Robert Andrews, Eagle Lake District Ranger and Designated Federal Officer, at (530) 257–4188; or RAC Coordinator, Heidi Perry, at (530) 252–6604.

Heidi L. Perry,

Acting Forest Supervisor.

[FR Doc. 03–3131 Filed 2–7–03; 8:45 am]

BILLING CODE 3410–11–M

DEPARTMENT OF COMMERCE

International Trade Administration

[A-570–853]

Bulk Aspirin from the People's Republic of China; Final Results of Antidumping Duty Review

AGENCY: Import Administration, International Trade Administration, Department of Commerce.

ACTION: Notice of Final Results of Antidumping Duty Review.

SUMMARY: On August 7, 2002, the Department of Commerce published the preliminary results of the administrative review of the antidumping duty order on bulk aspirin from the People's Republic of China. We gave interested parties an opportunity to comment on the preliminary results. Based upon our analysis of the comments received, we have made changes to the margin calculations presented in the final results of the review. We find that bulk aspirin from the People's Republic of China was not sold in the United States below normal value during the period of review.

EFFECTIVE DATE: February 10, 2003.

FOR FURTHER INFORMATION CONTACT: Julie Santoboni or Cole Kyle, Import Administration, International Trade Administration, U.S. Department of Commerce, 14th and Constitution Avenue, NW, Washington, DC 20230; telephone (202) 482–4194 or (202) 482–1503, respectively.

SUPPLEMENTARY INFORMATION:

Background

On August 7, 2002, the Department of Commerce (''the Department'') published in the **Federal Register** the preliminary results of its administrative review of bulk acetylsalicylic acid, commonly referred to as bulk aspirin, from the People's Republic of China (''PRC'') (*Bulk Aspirin from the People's Republic of China: Preliminary Results of Antidumping Duty Administrative Review and Changed Circumstances Review*, 67 FR 51167 (August 7, 2002) (''*Preliminary Results*'')).

Since the *Preliminary Results*, the following events have occurred: We received a case brief from the petitioner, Rhodia, Inc. (''petitioner''), on September 6, 2002. We received rebuttal briefs from the respondents, Shandong Xinhua Pharmaceutical Co., Ltd. (''Shandong'') and Jilin Henghe Pharmaceutical Company Ltd. (''Jilin''), on September 13, 2002. On October 25, 2002, the Department of Commerce published the final results of the changed circumstances review of bulk aspirin from the PRC, finding that Jilin Henghe Pharmaceutical is the successor-in-interest to Jilin Pharmaceutical Company Ltd. and Jilin Pharmaceutical Import and Export Corporation (*see Bulk Aspirin from the People's Republic of China: Final Results of Changed Circumstances Review*, 67 FR 65537 (October 25, 2002)).

The Department has now completed this antidumping duty administrative review in accordance with section 751 of the Tariff Act of 1930, as amended (the ''Act'').

Scope of Order

The product covered by this review is bulk acetylsalicylic acid, commonly referred to as bulk aspirin, whether or not in pharmaceutical or compound form, not put up in dosage form (tablet, capsule, powders or similar form for direct human consumption). Bulk aspirin may be imported in two forms, as pure ortho-acetylsalicylic acid or as mixed ortho-acetylsalicylic acid. Pure ortho-acetylsalicylic acid can be either in crystal form or granulated into a fine powder (pharmaceutical form). This product has the chemical formula $C_9H_8O_4$. It is defined by the official monograph of the United States Pharmacopoeia (''USP'') 23. It is classified under the Harmonized Tariff Schedule of the United States (''HTSUS'') subheading 2918.22.1000.

Mixed ortho-acetylsalicylic acid consists of ortho-acetylsalicylic acid combined with other inactive substances such as starch, lactose, cellulose, or coloring materials and/or other active substances. The presence of other active substances must be in concentrations less than that specified for particular nonprescription drug combinations of bulk aspirin and active substances as published in the *Handbook of Nonprescription Drugs*, eighth edition, American Pharmaceutical Association. This product is classified under HTSUS subheading 3003.90.0000. Although the HTSUS subheadings are provided for convenience and customs purposes, the written description of the merchandise under investigation is dispositive.